Deidra A Ansah1, Benjamin E Reinking1, Tarah T Colaizy1, Robert D Roghair1, Sarah E Haskell2. 1. Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, USA. 2. Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, USA, sarah-haskell@uiowa.edu.
Abstract
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are antidepressants prescribed in 10% of pregnancies in the USA. We have previously shown in preclinical studies that sertraline exposure impacts cardiomyocyte development, leading to reductions in left ventricular size and cardiac function. OBJECTIVES: We hypothesized that in utero SSRI exposure will lead to reduced left ventricular dimensions and cardiac function on echocardiography immediately after birth. METHODS: Twenty term infants with and 21 term infants without in utero exposure to SSRIs underwent echocardiograms to assess cardiac size and function. The exclusion criteria for infants were prematurity, small or large for gestational age, any respiratory or cardiovascular support needed after birth, and any major congenital malformation. RESULTS: Infants exposed to in utero SSRIs had significantly reduced right ventricular dimensions in the diastole (controls 1.0 cm [0.86, 1.20], SSRI 0.89 cm [0.730, 1.05], p = 0.03), and left ventricular lengths in the diastole and systole (diastole: controls 3.4 cm [3.25, 3.65], SSRI 3.25 cm [3.10, 3.45], p = 0.03; systole: controls 2.9 cm [2.65, 3.05], SSRI 2.6 cm [2.50, 2.85], p = 0.01). No differences were observed in cardiac function. Importantly, there were no differences in maternal conditions or infant birth weight, body surface area, or gestational age. CONCLUSIONS: Our findings suggest an association between in utero exposure to SSRIs and ventricular size in infants. Given the increasing use of SSRIs during pregnancy and the importance of early life programming on future cardiovascular health, larger studies need to be completed to determine if in utero SSRI exposure impacts ventricular size.
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are antidepressants prescribed in 10% of pregnancies in the USA. We have previously shown in preclinical studies that sertraline exposure impacts cardiomyocyte development, leading to reductions in left ventricular size and cardiac function. OBJECTIVES: We hypothesized that in utero SSRI exposure will lead to reduced left ventricular dimensions and cardiac function on echocardiography immediately after birth. METHODS: Twenty term infants with and 21 term infants without in utero exposure to SSRIs underwent echocardiograms to assess cardiac size and function. The exclusion criteria for infants were prematurity, small or large for gestational age, any respiratory or cardiovascular support needed after birth, and any major congenital malformation. RESULTS:Infants exposed to in utero SSRIs had significantly reduced right ventricular dimensions in the diastole (controls 1.0 cm [0.86, 1.20], SSRI 0.89 cm [0.730, 1.05], p = 0.03), and left ventricular lengths in the diastole and systole (diastole: controls 3.4 cm [3.25, 3.65], SSRI 3.25 cm [3.10, 3.45], p = 0.03; systole: controls 2.9 cm [2.65, 3.05], SSRI 2.6 cm [2.50, 2.85], p = 0.01). No differences were observed in cardiac function. Importantly, there were no differences in maternal conditions or infant birth weight, body surface area, or gestational age. CONCLUSIONS: Our findings suggest an association between in utero exposure to SSRIs and ventricular size in infants. Given the increasing use of SSRIs during pregnancy and the importance of early life programming on future cardiovascular health, larger studies need to be completed to determine if in utero SSRI exposure impacts ventricular size.
Authors: Nancy K Grote; Jeffrey A Bridge; Amelia R Gavin; Jennifer L Melville; Satish Iyengar; Wayne J Katon Journal: Arch Gen Psychiatry Date: 2010-10
Authors: Amish Jain; Afif F El-Khuffash; Bart C W Kuipers; Adel Mohamed; Kim A Connelly; Patrick J McNamara; Robert P Jankov; Luc Mertens Journal: J Pediatr Date: 2016-11-28 Impact factor: 4.406
Authors: Amish Jain; Adel Mohamed; Afif El-Khuffash; Kim A Connelly; Frederic Dallaire; Robert P Jankov; Patrick J McNamara; Luc Mertens Journal: J Am Soc Echocardiogr Date: 2014-09-23 Impact factor: 5.251
Authors: Georgios Schoretsanitis; Sara V Carlini; Majnu John; John M Kane; Kristina M Deligiannidis Journal: J Clin Psychopharmacol Date: 2021 Sep-Oct 01 Impact factor: 3.153
Authors: Mitchell E Kent; Bo Hu; Timothy M Eggleston; Ryan S Squires; Kathy A Zimmerman; Robert M Weiss; Robert D Roghair; Fang Lin; Robert A Cornell; Sarah E Haskell Journal: J Cardiovasc Pharmacol Date: 2022-08-01 Impact factor: 3.271